Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress. Issue 2 (March 2022)

• Record Type: Journal Article
• Authors: Rivera, Donna R.; Kluetz, Paul G.; Abdallah, Kald; Agrawal, Sundeep; Angus, Derek C.; Califf, Robert M.; Garrett-Mayer, Elizabeth; Hyer, Randall; Lowy, Douglas R.; Khleif, Samir N.
• Is Part Of: Cancer journal. Volume 28:Issue 2(2022)
• Page Start: 151
• Page End: 156
• Publication Date: 2022-03
• Subjects: COVID-19 -- clinical trial design -- real world data, pragmatic trials -- lessons learned; Cancer -- Periodicals; 616.994005
• DOI: 10.1097/PPO.0000000000000589
• Languages: English
• ISSNs: 1528-9117

Abstract

Abstract: Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled "Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned." This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.